Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Pipeline Review, H1 2018

June 2018 | 30 pages | ID: N195EEF6412EN
Global Markets Direct

Abstracts

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2018'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 6 molecules.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity, Epilepsy, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
• The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
Gila Therapeutics Inc
Novo Nordisk AS
Takeda Pharmaceutical Co Ltd
XL-protein GmbH
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
CG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-9748 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYY-1119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
Featured News & Press Releases
May 15, 2018: EU allocates EUR 3.6 million in funding for development of CombiGenes cutting-edge gene therapy technology
Feb 19, 2018: Final data from long-term study of CombiGene epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.
Dec 14, 2017: Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01
Dec 06, 2017: Initial data from the long-term study on CombiGene’s candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures
Nov 09, 2012: Novel treatment strategies for epilepsy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Gila Therapeutics Inc, H1 2018
Pipeline by Novo Nordisk AS, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by XL-protein GmbH, H1 2018
Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Gila Therapeutics Inc
Novo Nordisk AS
Takeda Pharmaceutical Co Ltd
XL-protein GmbH